Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 5, 2007

Advanced Proteome Therapeutics and Atreus Partner to Advance Protein-In Vivo Imaging Agents

  • Advanced Proteome Therapeutics (APT) and Atreus Pharmaceuticals are exploring the development of protein-in vivo imaging agents. The collaboration will use APT’s advanced site-directed peptide modification techniques.

    The first product is intended for imaging the earliest changes associated with rheumatoid arthritis. The resulting technology is expected to have clinical applications in the diagnosis and management of early rheumatoid arthritis.

    Under the agreement, Atreus will have the exclusive right to commercialize the jointly developed agents in return for revenue-sharing payments to APT. Atreus will provide technical, clinical, and market expertise to the program as well as intellectual property rights.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »